Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
V-01 bivalent SARS-CoV-2 vaccine
- Development stage
- Unknown
- Lead developer
- Livzon Pharmaceutical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
V-01 bivalent SARS-CoV-2 vaccine is a recombinant protein subunit vaccine developed by Livzon Pharmaceutical Group in collaboration with the Third People's Hospital of Shenzhen. It is a bivalent formulation designed to provide broad protection against SARS-CoV-2 variants, typically incorporating the Receptor Binding Domain (RBD) of the ancestral strain and a variant such as Beta (B.1.351) or Omicron. The vaccine utilizes a unique fusion protein platform (IFN-α-pan-RBD-Fc) where the RBD is fused to human interferon-alpha and an Fc fragment to enhance immunogenicity and target dendritic cells. It is primarily being evaluated as a heterologous booster dose in individuals who have previously received inactivated COVID-19 vaccines.
- Other names
- recombinant SAR-CoV-2 fusion protein bivalent vaccine
02
Targets
FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)RBD (SARS-CoV-2 spike receptor-binding domain)FCGRT (Neonatal crystallizable fragment receptor)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on V-01 bivalent SARS-CoV-2 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on V-01 bivalent SARS-CoV-2 vaccine.